Partnering
We intend to use research collaborations to leverage our technology platform across a wide range of potential opportunities. Because our technology enables efficient delivery of any new or existing drug to the brain, it should result in superior efficacy for treatment of brain diseases. Since the active molecules are chemically linked to Angiopep, we create patentable new chemical entities in the course of each project.
Out-licensing – ANG1005 // The Company’s strategy is to leverage its technological platform to create a new effective derivative of paclitaxel that crosses the blood-brain barrier. This compound, ANG1005 is targeted for future licensing once a Phase 1/2 clinical proof-of-concept is established the second half of 2008. With worldwide revenues of over US$3 billion, taxanes have been used in a number of cancer treatments over the past 10 years, including breast, lung and ovarian cancer as well as Kaposi’s sarcoma.
Contact us for more information on licensing opportunities for AngioChem's lead product known as ANG1005.
Co-development // AngioChem is open to collaborative research and development programs with biotechnology and pharmaceutical companies whose compounds' (small molecule or large molecules like monoclonal antibodies) therapeutic activity could be greatly enhanced by the AngioChem platform.
FACT SHEET